SWOG 9249--CARBOPLATIN/CYCLOPHOSPHAMIDE/G-CSF THERAPY FOLLOWED BY TAXOL

SWOG 9249--卡铂/环磷酰胺/G-CSF 治疗随后紫杉醇

• 批准号: 6282260
• 负责人: GERMAN BELTRAN
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282260
• 关键词: antineoplastics; carboplatin; clinical research; clinical trial phase I; colony stimulating factor; combination chemotherapy; cyclophosphamide; drug screening /evaluation; female; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer remission /regression; ovary neoplasms; paclitaxel; women's health

This study is to compare a dose-intensive regimen of carboplatin/ cyclophosphamide plus G-CSF followed by either standard dose paclitzaxel (Taxol) or dose intensive paclitaxel (Taxol)/G-CSF with respect to overall survival and incidence of pathologic complete response in patients with previously untreated Stage III suboptimal disease ovarian cancer of epithelial type. Also, this study compares dose intensive carboplatin/cyclophosphamide plus G-CSF followed by standard dose paclitaxel (Taxol) or dose intensive paclitaxel (Taxol)/G-CSF with respect to associated toxicities.

本研究旨在比较卡铂/顺铂的剂量强化方案， 环磷酰胺+G-CSF，随后给予标准剂量的紫杉醇 （泰素）或剂量密集型紫杉醇（泰素）/G-CSF， 总生存期和病理完全缓解的发生率 既往未经治疗的III期次优卵巢疾病患者 上皮型癌症。 此外，这项研究比较了剂量密集型 卡铂/环磷酰胺+G-CSF，随后标准剂量 紫杉醇（Taxol）或剂量密集型紫杉醇（Taxol）/G-CSF， 关于相关毒性。